GlobalData

Praluent (alirocumab) is a monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), an enzyme that…

This uptrend is primarily driven by rising diagnosis rates, notably in key markets like the US and China and approvals of 13…

Unmet needs in the kidney disease space include next-generation therapies with alternate mechanisms of action and enhanced…

VC investments increased by 11.2 per cent in Jan 2024, compared to Jan 2023

The acquisition of Catalent by Novo Holdings expects to see three new manufacturing sites added to Novo Nordisk’s arsenal, to…

Casgevy is the first CRISPR-based drug to receive marketing authorisation globally

The deal includes the novel HPN-217 and HPN-328 compounds, which are currently undergoing Phase II clinical trials for various…

Inflation in healthcare refers to the persistent increase in the cost of medical goods and services over time. This phenomenon is…

In 2017, Sanofi entered into a collaboration agreement with MedImmune (AstraZeneca) to jointly develop and commercialise Beyfortus

Moderna has Phase III pipeline candidates in four different indications (COVID-19, influenza, RSV, and cytomegalovirus) and is…